Citadel Advisors
CUE icon

Citadel Advisors’s Cue Biopharma CUE Stock Holding History

Citadel Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-337
Closed -$9.2K – 12912
2025
Q1 		$9.2K Sell
337
-23
-6% -$854 ﹤0.01% 13613
2024
Q4 		$11.8K Sell
360
-120
-25% -$4.51K ﹤0.01% 13531
2024
Q3 		$10.9K Buy
480
+53
+12% +$1.15K ﹤0.01% 13182
2024
Q2 		$15.9K Sell
427
-3
-0.7% -$148 ﹤0.01% 12813
2024
Q1 		$24.4K Sell
430
-313
-42% -$22.1K ﹤0.01% 12866
2023
Q4 		$58.9K Buy
743
+243
+49% +$17.4K ﹤0.01% 11610
2023
Q3 		$34.5K Buy
500
+53
+12% +$5.17K ﹤0.01% 12165
2023
Q2 		$48.9K Sell
447
-513
-53% -$60.3K ﹤0.01% 11825
2023
Q1 		$103K Buy
960
+757
+373% +$72.2K ﹤0.01% 11227
2022
Q4 		$17.4K Sell
203
-254
-56% -$23.2K ﹤0.01% 13252
2022
Q3 		$31K Sell
457
-280
-38% -$24.1K ﹤0.01% 11891
2022
Q2 		$55K Sell
737
-280
-28% -$32.8K ﹤0.01% 11865
2022
Q1 		$149K Sell
1,017
-250
-20% -$53K ﹤0.01% 11859
2021
Q4 		$430K Buy
1,267
+474
+60% +$183K ﹤0.01% 10041
2021
Q3 		$347K Buy
793
+100
+14% +$34.9K ﹤0.01% 10734
2021
Q2 		$242K Sell
693
-827
-54% -$321K ﹤0.01% 11765
2021
Q1 		$556K Buy
1,520
+570
+60% +$235K ﹤0.01% 9445
2020
Q4 		$357K Buy
950
+97
+11% +$38.8K ﹤0.01% 8763
2020
Q3 		$385K Buy
+853
New +$492K ﹤0.01% 7727

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Citadel Advisors's CUE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cue Biopharma (CUE) in Q2 2026: 25,633 shares worth $809K. The stake represents ﹤0.01% of the portfolio and ranks #8727 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CUE as recently as Q2 2024.

Citadel Advisors first reported a position in CUE in Q1 2020 and has held it in 16 quarters since. The position peaked at $6.69M in Q2 2020. 50 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Citadel Advisors held 25,633 shares of Cue Biopharma worth $809K as of Q2 2026.
  • Cue Biopharma was a new Citadel Advisors position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8727 holding.
  • Citadel Advisors first reported a position in Cue Biopharma in Q1 2020 and has held it in 16 quarters since.
  • Citadel Advisors's Cue Biopharma position peaked at $6.69M in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.